ASCO 2023

CDK4/6i in EBC: Have abema and ribo arrived in the early setting? Insights from North America and Europe

ADC revolution: How can the new results be integrated in clinical practice? Which studies are in sight and which ones do we need in the future?

Discussions and controversies on social-media: what is the impact of science-twitter discussions on the everyday practice in oncology?

Sonia trial: How does the new data change clinical practice - or does it at all? Insights from Italy, United States and Germany.

Expanding CDK4/6i therapy in EBC: How to select patients for the right therapy?

PART1: How to de-escalate chemotherapy? What is the best strategy to identify patients who don´t need chemotherapy?

CDK4/6 inhibitors in EBC: Amazing data, but longer follow up needed!

PART2: Trying to understand optimal therapy for pre-menopausal women - promising results, but still long way to go!

New data on Ribocilib in adjuvant setting EBC: What does it change immediately, what changes are expected in the future? Perspectives from Europe and Northern America

Data from Meta-Analyses of almost 15k Patients: Who benefits from ovarian function suppression?

Chemotherapy de-escalation in HER2+ patients: Consequences of the PHERGain data on daily practice?!

Palbociclib after Palbociclib might not be the best option

10 years update on ShortHER

From PENELOPE-B to SURVIVE

Ribociclib has arrived in the adjuvant setting

SOC of ovarian ablation confirmed in meta-analysis.

TILs in HER2+ disease - prognostic, but not enough to deescalate

Ovarian function - Ovarian suppression not necessary in young patients?

De-escalation of CT for early BC

First data with adjuvant ribociclib

Response adapted, chemotherapy-free option in HER2+ EBC

Early follow-up shows clear benefit

Chemo-immunotherapeutic signals especially in HER2low possibly predictive of chemotherapy response in EBC

My EBC highlights from ASCO23

Discussions on CDK4/6 inhibitors in EBC

1/3 of patients with HER2+ in future without chemotherapy?

More CDK4/6 options for EBC patients

Another proof of efficacy of immunotherapy in advanced TNBC

Ribociclib improves iDFS

White blood cells with increasing prognostic relevance? Data from the GeparNuevo Study

Can we preserve our patients form chemotherapy?

PHERGain opens the possibility to avoid chemotherapy in HER2+ breast cancer

Analyses of ctDNA in PENELOPE-B: Test methods are increasingly accurate

Young patients benefit from ovarian suppression

Checkpoint inhibition in endometrial cancer: new therapy algorithms needed

A challenge for clinical management

Tumor-informed ctDNA likely prognostic for relapse in ER positive and HER2 negative EBC

TILs subtypes are associated with clinical features and prognosis in HR+/HER2- BC

Practice changing or not quite yet?

TILs are prognostic but not predictive in HER2+ EBC

SOC der ovarialen Ablation in der Metaanalyse bestätigt

1/3 der Patientinnen mit HER2+ zukünftig ohne Chemotherapie?

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen der Chemotherapie

TILs w rakach HER2+ - znaczenie rokownicze, ale nie droga do deeskalacji leczenia

Von PENELOPE-B zur SURVIVE

Czy wystarczy, aby zmienić standardy?

Tumor-informed ctDNA wahrscheinlich prognostisch für einen Rückfall beim ER positive und HER2 negative eBC

Ovar Funktion - Ovarielle Supression verzichtbar bei jungen Patientinnen?

PHERGain abre la posibilidad de evitar la quimioterapia en el cáncer de mama HER2+

Kolejny dowód na skuteczność immunoterapii w zaawansowanym raku trójujemnym

I miei punti salienti di ASCO23

Palbociclib después de Palbociclib podría no ser la mejor opción

NATALEE nicht überraschend aber überzeugend positiv

Eine Herausforderung für das klinische Management

Primele date cu ribociclib adjuvant

TILs sind prognostisch aber nicht prädiktiv beim HER2+ eBC

TILs Subtypen sind assoziiert mit klinischen Merkmalen und Prognose beim HR+/HER2- BC

Eine Herausforderung für viele Patienten, wenig Doktoren

Response adaptierte, Chemotherapie-freie Option beim HER2+ eBC

Updates on ADCs in metastatic breast cancer

E-Health Applications in Oral Cancer Therapy

The start of precision medicine in HR+ breast cancer

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

Molecular imaging for endocrine responsivness

What is the optimal therapie sequence for HR+ MBC patients?

Continued OS benefit for Sacituzumab Govitecan

CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo studio PALMIRA

Mises à jour sur les ADC dans le cancer du sein métastatique

Aggiornamenti sugli ADC nel carcinoma mammario metastatico

Update ADC efficacy

CDK4/6 Sequencing? ESR-1 not ready for prime time? Palbo rechallenge?

The value of eHealth

CDK4/6i in first line and beyond & Biomarkers

Part2: Important update on testosterone-recovery

AI for prediction in local prostate carcinoma

PSA nadir 6 month after Radiotherapy is strong prognostic marker for survival

LuPARP combination study: LuPSMA and Olaparib in mCRPC

Confirming results for PARPi in mCRPC

Reassuring real-world data!

Over-staging of bone scan compared with PSMA PET/CT

DEAR trial: real-world comparator analyses of ARIs

ARASEC: ADT + Daralutamide for mHSPC

PAPR-inhibitors: Patient-selection matters!

PRL-02: Intramuscular arbiraterone

TALAPRO-2: Results and controversies

Part 1: Important update on testosterone-recovery

PEACE 1 - results and controversies

Metastasis-directed for prostate cancer

Intensified or de-intensified therapy in mHSPC

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

PARP-inhibitors: La selección de pacientes es importante

Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT

Intensifierad eller de-intensifierad behandling vid mHSPC?

PSA nadir 6 månader efter radioterapi är en prognostisk markör för överlevnad

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

PARPi in PCa: more genetic testing is required as PRO data demand better patient selection

What is your preferred sequence in 1st line treatment and how you treat after progress?

Triple therapy in mCSPC - which is the ideal partner for radiotherapy? And which patients should received irradiation?

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

The beginning of a new era in urothelial cancer?!

Q-TWiST in the therapy of aUC

Extent of lymphadenectomy in cystectomy

Enfortumab vedotin + pembrolizumab 1stL in cisplatin-ineligible patients

First line in cisplatin-ineligible advance urothelial cancer: It´s getting busy out there

Targeted therapies in advanced urothelial cancer: The renaissance?!

New SoC option for metastatic bladder cancer

New standard for MIBC

FGFR inhibition

Terapias dirigidas al cáncer urotelial avanzado: ¡¿El renacimiento?!

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

Nouvelles options de soins standard pour le cancer de la vessie métastatique

Primera línea en cáncer urotelial avanzado no elegible para cisplatina: Hay mucho trabajo ahí fuera

The efficacy of neo-adjuvant therapy (ddMVAC, Cisplatinum)

The efficacy of FGFR targeting

Update EV/Pembro, Avelumab Maintenance

Primary endpoint not reached: what do we learn from CONTACT-03 results?

The impact of microbiome and supplements on therapy efficacy

Long term follow up in advanced renal cell cancer: Is everything clear, yet?

Non ccRCC: how should we treat patients today?

IO rechallenge in mRCC

Update and take home message of 1st Line mRCC

News from the adjuvant

New data non ccRCC

1st Line therapy RCC: which combination to choose?

Long-term follow-up for IO/TKI in mRCC

New standard for 2nd line RCC?

Lenvatinib + pembrolizumab in non-clear cell renal cell carcinoma

ADAURA: Osimertinib improves survival in the treatment of EGFRm rNSCLC

The value of perioperative chemo-IO in rNSCLC and the importance of staging

A new standard of care

A chemo-free preop. IO strategy?

More options in the perioperative setting

CheckMate 9LA: 4‑year clinical update

Role of periopertative IO confirmed

An imperfect analysis, but perfect results

A new standard of care for operated patients with eGFRmut adenocarcinoma

Which should we prefer: neoadjuvant, adjuvant or perioperative chemo/IO?

Another neoadjuvant chemo/IO option

Confirmation of neoadjuvant immunotherapy

OS benefit from EGFR receptor TKI

Induction options in the perioperative setting

Adjuvant IO in KRASm patients

Perioperative treatment

EGFR testing necessary in the adjuvant setting

ADAURA - results and controversies

ADAURA - Discussion closed?

Adjuvant and neoadjuvant strategies in resectable NSCLC

Added benefit of perioperative chemo/IO in stage 2-3b NSCLC

Rolle der periopertativen IO bestätigt

ADAURA- discussie gesloten?

Stratégies adjuvantes et néoadjuvantes dans le CBNPC résécable

Que devrions-nous préférer: traitement néoadjuvant, adjuvant ou chimio/IO périopératoire?

Más opciones en el entorno perioperatorio

Un nouveau standard therapeutique pour les patients opérés d’un adenocarcinome EGFR muté

Toegevoegde waarde van periperatief chemo-immuno bij stadium II-IIIB NSCLC

TTF-treatment requires further studies

Pembro + chemo in pts with TKI-resistant EGFRm / Sunvozertinib - a drug for Exon20 insertions

Zorifertinib: an option when osimertinib is not available

Sotorasib: clear clinical benefit, but short follow-up time

Does ADC + chemo + IO replace the existing concepts?

Update on KRASG12Cm treatment options - how to proceed?

TROP2-ADC shows high response rates in 1L-combination therapy, but safety must be observed

Stopping treatment is ok

IO in EGRF positive patients post TKI

ADC + ICI ± Pt-CT in patients with aNSCLC

CORRELATE - a real world analysis

LUNAR: TTF medical device shows OS-benefit, but more information needed

Hyperfractionation - an interestingh concept, but not for every patient

New data from another BiTE

A positive trial with no impact

Can we incoporate biomarkers in SCLC treatment?

Hyperfractionated radiotherapy for SCLC

More BiTEs, more possibilities

Treatment strategies in SCLC

Stratégies de traitement dans le SCLC

Más BiTEs, más posibilidades

Kunnen we biomarkers gebruiken om behandeling te selecteren voor SCLC?

ONCOalert (inclusive patient advocates) consensus on the results of the PROspect trial

No practice-changing data in mesothelioma, other studies to await

Immune checkpoint inhibitors in malignant mesothelioma

Immun-Checkpoint-Inhibitoren beim malignen Mesotheliom